Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2019 1
2023 3
2024 3
2025 4
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial.
Khanani AM, Patel SS, Staurenghi G, Tadayoni R, Danzig CJ, Eichenbaum DA, Hsu J, Wykoff CC, Heier JS, Lally DR, Monés J, Nielsen JS, Sheth VS, Kaiser PK, Clark J, Zhu L, Patel H, Tang J, Desai D, Jaffe GJ; GATHER2 trial investigators. Khanani AM, et al. Lancet. 2023 Oct 21;402(10411):1449-1458. doi: 10.1016/S0140-6736(23)01583-0. Epub 2023 Sep 8. Lancet. 2023. PMID: 37696275
Treatment intervals with first-generation anti-vascular endothelial growth factor drugs: evaluating the unmet need in a real-world neovascular age-related macular degeneration national database.
Zarranz-Ventura J, Garay-Aramburu G, Calvo P, Zapata MA, Arruabarrena C, Arnáiz P, García-Lunar P, Sararols-Ramsay L; FRB SPAIN study group. Zarranz-Ventura J, et al. Among authors: sararols ramsay l. Eye (Lond). 2025 Dec;39(18):3306-3313. doi: 10.1038/s41433-025-03996-8. Epub 2025 Oct 16. Eye (Lond). 2025. PMID: 41102554 Free PMC article.
Brolucizumab clinical and safety outcomes in a neovascular age-related macular degeneration national database: Fight Retinal Blindness Spain (FRB Spain).
Zarranz-Ventura J, Marías-Pérez S, Martin-Pinardel R, Fernandez-Bonet M, Pina-Marin B, Cobos E, Rodríguez-Fernandez CA, Parrado-Carrillo A, Alarcón-Valero I, Barnes C, Cilveti E, Aramburu-Claveria J, Ascaso-Puyuelo FJ, Calvo P, Ruiz-Del-Tiempo MP, Susanna-González G, Figueras-Roca M, Casaroli-Marano RP, Bernal-Morales C; Fight Retinal Blindness Spain (FRB Spain) investigators. Zarranz-Ventura J, et al. Eye (Lond). 2025 Aug;39(12):2407-2414. doi: 10.1038/s41433-025-03871-6. Epub 2025 Jun 5. Eye (Lond). 2025. PMID: 40473932
Fluid fluctuations assessed with artificial intelligence during the maintenance phase impact anti-vascular endothelial growth factor visual outcomes in a multicentre, routine clinical care national age-related macular degeneration database.
Martin-Pinardel R, Izquierdo-Serra J, Bernal-Morales C, De Zanet S, Garay-Aramburu G, Puzo M, Arruabarrena C, Sararols L, Abraldes M, Broc L, Escobar-Barranco JJ, Figueroa M, Zapata MA, Ruiz-Moreno JM, Parrado-Carrillo A, Moll-Udina A, Alforja S, Figueras-Roca M, Gómez-Baldó L, Ciller C, Apostolopoulos S, Mishchuk A, Casaroli-Marano RP, Zarranz-Ventura J; from the FRB SPAIN-IMAGE Project Investigators. Martin-Pinardel R, et al. Br J Ophthalmol. 2025 Sep 23;109(10):1161-1170. doi: 10.1136/bjo-2024-325615. Br J Ophthalmol. 2025. PMID: 39848699
Macular Neovascularization Type Influence on Anti-VEGF Intravitreal Therapy Outcomes in Age-Related Macular Degeneration.
Izquierdo-Serra J, Martin-Pinardel R, Moll-Udina A, Bernal-Morales C, Garay-Aramburu G, Sanchez-Monroy J, Arruabarrena C, Fernandez-Hortelano A, Figueroa MS, Abraldes M, Lavid de Los Mozos FJ, Zapata MA, Ruiz-Moreno JM, Broc-Iturralde L, Gonzalez-Guijarro J, Escobar-Barranco JJ, Gallego-Pinazo R, Parrado-Carrillo A, Dotti-Boada M, Alforja S, Figueras-Roca M, Barthelmes D, Gillies MC, Casaroli-Marano RP, Zarranz-Ventura J; Writing Committee of the Fight Retinal Blindness Spain (FRB! Spain) Users Group. Izquierdo-Serra J, et al. Ophthalmol Retina. 2024 Apr;8(4):350-359. doi: 10.1016/j.oret.2023.10.022. Epub 2023 Nov 2. Ophthalmol Retina. 2024. PMID: 37924946
Fight Retinal Blindness SPAIN. Report 3: clinical outcomes of vascular endothelial growth factor inhibitors in low vision eyes with neovascular age-related macular degeneration. A national database study.
Puzo M, Calvo-Perez P, Bartol-Puyal F, Sanchez-Monroy J, Martin-Pinardel R, Parrado-Carrillo A, Moll-Udina A, Bernal-Morales C, Sanchez-Vela L, Sararols-Ramsay L, Garay-Aramburu G, Arruabarrena C, García-Arumí J, Abraldes M, Ruiz-Moreno JM, Valldeperas X, Velázquez-Villoria D, Escobar-Barranco JJ, Gallego-Pinazo R, Figueroa MS, Figueras-Roca M, Barthelmes D, Gillies MC, Casaroli-Marano RP, Zarranz-Ventura J; from the writing committee of the Fight Retinal Blindness Spain (FRB! Spain) Users Group. Puzo M, et al. Among authors: sararols ramsay l. Eye (Lond). 2024 Dec;38(18):3450-3458. doi: 10.1038/s41433-024-03322-8. Epub 2024 Sep 21. Eye (Lond). 2024. PMID: 39306616 Free PMC article.
11 results